VWA3A Inhibitors
VWA3A inhibitors pertain to a chemical class that targets the von Willebrand factor A domain-containing protein 3A (VWA3A), which is a specific protein involved in a variety of cellular processes. The von Willebrand factor A (VWA) domain is known for its presence in extracellular matrix proteins, and it plays a crucial role in protein-protein interactions. VWA3A inhibitors are designed to interfere specifically with the function of the VWA3A protein by binding to its active site or to a site that alters its conformation and, thus, its activity. This interaction is highly specific and requires that the inhibitors have a particular structure that complements the VWA3A domain, often achieved through a meticulous design process that takes into account the intricate details of the protein's shape and charge distribution.
The development of VWA3A inhibitors involves a sophisticated understanding of the protein's structure and the molecular dynamics that govern its function. Researchers utilize various techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to discern the three-dimensional structure of VWA3A, enabling them to identify potential binding sites for inhibitors. Computational methods, including molecular docking and virtual screening, are often employed to predict how small molecules might interact with the protein and how they might be optimized to enhance their inhibitory action. The inhibitors themselves are typically small organic molecules that can be synthesized and modified to improve their affinity for the VWA3A protein and their ability to disrupt its function. The specificity of VWA3A inhibitors is of paramount importance, as it ensures that they target only the intended protein without affecting other proteins with similar domains, thereby minimizing off-target effects.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs). By inhibiting CDKs, it can disrupt the cell cycle, potentially reducing VWA3A expression as it may be regulated during cell cycle progression. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Inhibition of PI3K can affect AKT signaling, which may indirectly influence VWA3A by altering cell survival and protein synthesis pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to Wortmannin. It prevents AKT activation, and through this, it could indirectly decrease VWA3A activity by affecting downstream signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting MEK, U0126 can prevent the activation of ERK, potentially affecting the expression or activity of VWA3A. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK. Inhibition of this kinase can influence inflammatory responses and cell differentiation processes, which may indirectly affect VWA3A function or expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, which affects cell growth and proliferation. Inhibiting mTOR can lead to a decrease in protein synthesis and may influence VWA3A expression or function as part of the cellular response. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. It can accumulate misfolded proteins, leading to ER stress and potentially downregulating protein synthesis, which could include VWA3A. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, leading to increased cytosolic calcium and ER stress. This could affect VWA3A by modulating its expression through stress response pathways. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor, which could decrease VWA3A levels by broadly reducing protein translation, including the translation of VWA3A. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, similar to U0126. It also prevents ERK activation, which could affect the signaling pathways that regulate VWA3A expression or activity. | ||||||